MARKET PULSE-Chelsea, Retrophin, YRC Worldwide, Mannkind, Target
(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stocks were little changed in volatile trading on Friday as a weaker-than-expected payrolls report was partly blamed on frigid weather, leaving traders in search of further clues on the state of the economy. The Dow Jones industrial average was down 0.18 percent at 16,415.11, the S&P 500 was down 0.08 percent at 1,836.61 and the Nasdaq Composite was down 0.02 percent at 4155.18.
** CHELSEA THERAPEUTICS INTERNATIONAL LTD, $2.515, -28.75 pct
U.S. Food and Drug Administration reviewers said a treatment developed by Chelsea for a rare type of low blood pressure lack evidence that the drug's benefit is durable over a longer period of time, according to documents on the FDA's website.
** RETROPHIN INC, $10.85, +27.65 pct
The pharmaceutical company said it expects gross proceeds of $40 million from a share offering and use it to get regulatory approval for its nasal spray to aid milk ejection for breastfeeding mothers. It will also use the fund to start trials for some of its experimental drugs.
** YRC WORLDWIDE INC, $12.42, -20.74 pct
Workers at the trucking company represented by the Teamsters union rejected a contract extension that the company proposed, putting a plan to restructure its debt in jeopardy. Continued...